20.06.2014 • News

Recipharm and CTC in Clinical Trial Collaboration

CTC Clinical Trial Consultants of Uppsala, Sweden, and compatriot Recipharm Pharmaceutical Development of Solna, Stockholm, Sweden, have begun a collaboration to offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material.

The scope of the cooperation will extend to planning, performing and evaluation of the clinical trial.

Maria Lundberg, general manager Recipharm Pharmaceutical Development, said the link-up will allow the two companies to offer customers faster and more cost-efficient phase I studies. "We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies."

CTC has "excellent experience" in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset), Lundberg noted.

Beyond shortening project timelines, Bengt Dahlström, CEO of CTC Clinical Trial said the systematic integrated approach will help the companies to obtain more information on the desirable properties of the drug formulation.

"Adaptive design," he said, "is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol."

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.